• +91 9169164321 (Asia)
  • +1(646)-781-7170 (Int'l)
  • help@24lifesciences.com
Cart (0)

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline Review, H1 2020

report cover
  • 30 April 2020
  • Pharmaceuticals
  • 45 Pages
  • Report Code: 24LS-1838
  • Formate :   
Download FREE Report Sample Download PDF File

Thrombotic Thrombocytopenic Purpura Pipeline Review H1 -MARKET ADVISORY SERVICES

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline Review, H1 2020

Summary

We latest Pharmaceutical and Healthcare disease pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H1 2020, provides an overview of the Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline landscape.

Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, heart rate, shortness of breath, speech changes, weakness and yellowish color to the skin (jaundice). Treatment includes surgery to remove spleen and drugs that suppress the immune system, such as corticosteroids.

Report Highlights

We Pharmaceutical and Healthcare latest pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Overview
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Companies Involved in Therapeutics Development
KM Biologics Co Ltd
Lee's Pharmaceutical Holdings Ltd
Sanofi
Takeda Pharmaceutical Co Ltd
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Drug Profiles
apadamtase alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
caplacizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate ADAMTS13 for Thrombotic Thrombocytopenic Purpura - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZK-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products
Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Product Development Milestones
Featured News & Press Releases
Sep 21, 2018: A Trojan Horse delivery of possible treatment for a rare, potentially deadly, blood-clotting disorder
Sep 14, 2017: Engineered Therapy for Blood Clotting Disorder Shows Early Promise
Mar 22, 2017: Shire receives FDA Fast Track designation for recombinant ADAMTS13 (SHP655) for treatment of hereditary thrombotic thrombocytopenic purpura
May 25, 2016: Baxalta Reports Positive Phase 1 Results for BAX 930, Investigational Recombinant ADAMTS13 to Treat Hereditary Thrombotic Thrombocytopenic Purpura
Mar 24, 2016: U.S. FDA Grants Orphan Drug Designation to Anfibatide for Treatment of Thrombotic Thrombocytopenic Purpura
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables

Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by KM Biologics Co Ltd, H1 2020

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2020

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Sanofi, H1 2020

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects, H1 2020

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products, H1 2020List of Figures

Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020
KM Biologics Co Ltd

Lee's Pharmaceutical Holdings Ltd

Sanofi

Takeda Pharmaceutical Co Ltd

CHOOSE YOUR BUYING OPTION COVID-19 Revised Pricing Of the Month

SECURITY ASSUREDpayment image

Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

CHECK TODAYS BEST PRICE

BEST PRICE: $1540

SOME OF OUR CLIENTS

OUR KEY POINTS

  • Comprehensive Research

    Offers Penetrative insights & holistic understanding of the market

  • Data Accuracy & Reliability

    Strictly follows the Research Meth-odology for flawless results

  • Competitive Pricing

    Ensure the best and affordable pricing

  • Security & Confidentiality

    All your transactions are secured end-to-end, ensuring a satisfactory purchase